Clinical and CT/MRI features of hepatic AL amyloidosis: preliminary experience in 10 cases
-
By
-
Yanyan Zhang
-
Wei Wang
-
Wenyan Song
-
Jing Chang
-
Hongjun Li
-
June 19, 2026
-
Clinical Scorecard: Clinical and Imaging Characteristics of Hepatic AL Amyloidosis: Insights from a Study of 10 Patients
At a Glance
| Category | Detail |
|---|
| Condition | Hepatic AL Amyloidosis |
| Key Mechanisms | Extracellular deposition of amyloid proteins leading to organ dysfunction. |
| Target Population | Patients with confirmed hepatic AL amyloidosis. |
| Care Setting | Clinical and imaging evaluation in a hospital setting. |
Key Highlights
- Hepatomegaly was present in all patients (100%).
- Laboratory findings included markedly elevated alkaline phosphatase and gamma-glutamyl transferase (100%).
- CT imaging showed diffuse hepatomegaly with decreased hepatic attenuation in all cases.
- MRI revealed marked hepatomegaly with smooth margins and vascular rarefaction.
- Recognition of specific imaging findings can improve diagnostic accuracy.
Guideline-Based Recommendations
Diagnosis
- Suspect hepatic AL amyloidosis in patients with unexplained hepatomegaly and elevated ALP/GGT.
Management
- Timely recognition and diagnosis are crucial for improving patient outcomes.
Monitoring & Follow-up
- Monitor for specific imaging findings such as delayed enhancement and periportal edema.
Risks
- Hepatic amyloidosis carries a poor prognosis if not diagnosed early.
Patient & Prescribing Data
10 patients with confirmed hepatic AL amyloidosis.
No specific treatment insights provided in the study.
Clinical Best Practices
- Maintain a high index of suspicion for hepatic AL amyloidosis in relevant clinical scenarios.
- Utilize imaging findings to support diagnosis.
Related Resources & Content
